Trump’s 340B Proposal Puts Patients Over Criminals and Big Hospital Profits

The U.S. Department of Health and Human Services announced on July 31, 2026, that it would revise the terms of a pilot program under the 340B Drug Pricing Program, prompting immediate backlash from hospital groups. The change, effective January 1, 2027, shifts how pharmaceutical companies can offer rebates to participating healthcare providers. Instead of requiring upfront discounts, the new rule allows companies to submit “timely” rebates after the purchase of certain medications. This shift has raised concerns among hospital administrators and advocacy groups, who argue the policy could reduce financial support for safety-net institutions. The 340B program, established in 1992, enables eligible hospitals and clinics to purchase medications at significantly reduced prices compared to retail costs. These savings are intended to help cover the cost of care for low-income patients and underserved populations. The pilot initiative, initially proposed in 2025, aimed to test whether allowing pharmaceutical firms to offer post-purchase rebates instead of upfront discounts could improve transparency and ensure more predictable funding for healthcare providers. However, the revised proposal has been criticized for potentially limiting the amount of money available to hospitals, especially during periods of high demand or financial strain. According to officials with the Health Resources and Services Administration (HRSA), which oversees the 340B program, the changes are designed to enhance oversight and promote long-term sustainability. “This revised pilot helps modernize program oversight by improving visibility into 340B transactions while helping preserve the program’s long-term sustainability for the patients and communities it was created to serve,” said Tom Engels, head of HRSA. The agency claims the new approach will create clearer records of transactions, making it easier to monitor compliance and prevent misuse of funds. The pilot focuses on drugs included in the first two rounds of the Medicare Part D drug price negotiation program, which seeks to lower prescription drug costs for beneficiaries. These include several widely used medications, such as insulin and cholesterol-lowering agents. Under the revised rules, pharmaceutical companies must submit rebate data within 90 days of a transaction, rather than providing upfront discounts. While this is meant to streamline the process, critics argue it could result in delayed payments, complicating budget planning for hospitals already facing financial challenges. Hospital associations, including the American Hospital Association and the Healthcare Financial Management Association, have expressed alarm over the potential impact of the revised pilot. They warn that the shift away from upfront discounts could lead to unpredictable cash flow, particularly for smaller and rural facilities that rely heavily on the 340B program to maintain operations. “This change threatens the stability of our institutions and the ability to provide care to vulnerable patients,” said one hospital administrator in a statement released earlier this week. The controversy has also drawn attention from lawmakers and patient advocates. Some members of Congress have called for a public hearing to examine the implications of the revised pilot, arguing that the decision should involve broader stakeholder input before implementation. Meanwhile, patient advocacy groups have emphasized that the 340B program plays a critical role in ensuring affordable medication access for millions of Americans, particularly those living in poverty or with chronic conditions. As the deadline for the pilot’s launch approaches, the debate over its structure continues to intensify. With the final details still being finalized, the coming months will likely see increased scrutiny from both the medical community and policymakers. The outcome of this policy shift could have far-reaching consequences for the financial health of hospitals and the accessibility of medications for patients nationwide.